Actively Recruiting
Optimizing Neoadjuvant Treatment Using Circulating Tumor DNA and Endocrine Response A Randomized Study Comparing Endocrine Therapy and Chemotherapy in Early and Locally Advanced HR-positive, HER2-negative Breast Cancer
Led by Austrian Breast & Colorectal Cancer Study Group · Updated on 2026-08-19
350
Participants Needed
14
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effectiveness and quality of life outcomes of neoadjuvant endocrine therapy compared to chemotherapy in participants with early or locally advanced hormone receptor-positive, HER2-negative breast cancer who have no detectable circulating tumor DNA ctDNA in their blood. This study focuses on determining if endocrine therapy is at least equivalent to chemotherapy for those who respond to initial aromatase inhibitor treatment, using the modified preoperative endocrine prognostic index PEPI score as the main measure. Participants initially provide blood and tumor samples for ctDNA testing using the SignateraTM test. They then take aromatase inhibitor therapy for 4 weeks during a Run-in Phase, with a tumor biopsy after 3 weeks to assess Ki-67 levels. Based on ctDNA results and Ki-67 values, participants are assigned to one of three groups neoadjuvant aromatase inhibitor or tamoxifen treatment, neoadjuvant chemotherapy for endocrine responders, or chemotherapy for non-responders. Treatment lasts 6 to 8 months depending on the group. During the study, participants visit the clinic several times, including before starting treatment, after 3 weeks of endocrine therapy, before beginning the main treatment, mid-therapy, after treatment completion, for surgery and post-surgery checkups, and annually for 5 years after surgery. They provide blood samples for ongoing ctDNA assessment and complete questionnaires on quality of life, symptoms, and sexual health. The study tracks outcomes like PEPI score at surgery and long-term survival and disease-free survival over 5 years.
CONDITIONS
Brief Title
ABCSG 61 / TEODOR : Neoadjuvant TrEatment Optimization Driven by Circulating Tumor DNA and endOcrine Responsiveness
Research Team
K
Katharina Jarolim, PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here